News

Up one level
Watch the Opening Session of CLINAM 2014 on YouTube

Watch the Opening Session of CLINAM 2014 on YouTube

The Opening Session of the European Summit for Clinical Nanomedicine 2014 is now available on YouTube.

Read More…

IMI 2 info day – registration now open

IMI 2 info day – registration now open

Registration for the IMI 2 Info Day on 30 September in Brussels, Belgium is now open via the event web page.

Read More…

Interview: Europe as leaders in nanomedicine: let's go for it!

Interview: Europe as leaders in nanomedicine: let's go for it!

Dr Laurent Lévy speaks to Hannah Stanwix, Commissioning Editor. L Lévy is the Co-Founder, CEO, President of the Executive Board and a shareholder of Nanobiotix, a clinical-stage nanomedicine company pioneering NanoXray, a novel approach for the local treatment of cancer. L Lévy is the Vice-Chairman of the European Technology Platform on Nanomedicine (ETPN)

Read More…

The new Fit for Health 2.0 Partner Search and Matchmaking tool is online

The new Fit for Health 2.0 Partner Search and Matchmaking tool is online

euMatch is the new matchmaking tool supporting partnering and partner search for your efficient participation in EU Horizon 2020 programme

Read More…

SME Instrument: 6 lessons learnt from the first EC evaluation

SME Instrument: 6 lessons learnt from the first EC evaluation

As the SME Instrument is a brand new funding opportunity, it was not known what to expect from the first round of applications. As it is said on many occasions, the Instrument is very selective and only the best of the best can succeed.

Read More…

Pfizer, Merck Focusing On Nanomedicine As Next Disruption In Pharma

Pfizer, Merck Focusing On Nanomedicine As Next Disruption In Pharma

Nanomedicine is an emerging space with many companies spending on research to explore this field in greater depth. Nanoparticles, which are of one to 100 nm, because of their characteristic of being very small are perfect for reaching cellular levels. Research in this field can open new avenues of treating diseases which were initially considered untreatable.

Read More…

Revised Work Programmes 2014–2015 in Horizon 2020

Revised Work Programmes 2014–2015 in Horizon 2020

The parts of the Work Programmes 2014–2015 that relate to 2015 (topics, dates, budget) have, with these revised versions, been updated.

Read More…

SMEs Business rounds in Argentina

SMEs Business rounds in Argentina

The ETP Nanomedicine is currently expanding its range of collaborations with non-European countries in order to create new opportunities for its members. Besides USA, first contacts have been established with Argentina.

Read More…

Webinar “Clinical Trials in Horizon 2020”

Webinar “Clinical Trials in Horizon 2020”

The Fit4Health project organises a webinar on 9th September focussed on the description and implementation of clinical trials in Horizon 2020 proposals.

Read More…

DG SANCO launched a Public Consultation on the Determination of Potential Health Effects of Nanomaterials Used in Medical Devices

DG SANCO launched a Public Consultation on the Determination of Potential Health Effects of Nanomaterials Used in Medical Devices

The European Commission and the Scientific Committee on Emerging Newly Identified Health Risks have launched a public consultation on the Preliminary opinion ‘Guidance on the Determination of Potential Health Effects of Nanomaterials Used in Medical Devices’.

Read More…

EuroNanoMed II - Concluded projects funded under the 1st Joint Transnational Call

EuroNanoMed II - Concluded projects funded under the 1st Joint Transnational Call

The projects launched in the 1st Joint Translational Call in 2009 for research groups operating in the EuroNanoMed II partner countries have been finished.

Read More…

IMI2: Idea generation and development of Call topics

IMI2: Idea generation and development of Call topics

The Innovative Medicines Initiative2 launched on open consultation for Idea generation and development of Call topics

Read More…

Nanotech Japan Cluster Mission 2015

Nanotech Japan Cluster Mission 2015

The EU-Japan Centre is organizing a nanotech mission to Japan targeting EU Cluster and SMEs operating in that sector.

Read More…

 "Nanobiomedicine" - a new journal launched within the field of Nanomedicine

"Nanobiomedicine" - a new journal launched within the field of Nanomedicine

Nanobiomedicine is an international, peer-reviewed, open access scientific journal with an innovative approach, being open to both the readers and the authors (no fee requested).

Read More…

CTO of the year award 2014

CTO of the year award 2014

CTO (Chief Technology Officer) of the Year award is a new platform to promote the importance of technology and innovation in Europe. The award will be given to the most innovative technology leader of a highly successful European company: a person who is both an inspiring leader and a foresighted technology manager. The award will recognize the most successful technology leaders in two categories: SMEs and large corporations.

Read More…

Press Release: New European research project aims to tackle antibiotic resistance issue raised by WHO via inhalable nanotherapeutics

Press Release: New European research project aims to tackle antibiotic resistance issue raised by WHO via inhalable nanotherapeutics

A new research project (PneumoNP) is aimed at tackling antibiotic resistance in respiratory tract infections via the use of inhalable nanotherapeutic compounds. Funded under the FP7 programme by the European Commission, the 4-year long PneumoNP project brings together top research institutes, universities, clinicians and enterprises from 6 EU member states.

Read More…

Latest EuroNanomed 2 video

Latest EuroNanomed 2 video

EuroNanomed 2 releases a 7-minute video to promote drug delivery using Nanoparticles

Read More…

First JTI calls for proposals in Horizon 2020 published

First JTI calls for proposals in Horizon 2020 published

Five Public-private partnerships between the EC and industry have today published their first call for proposals, among them IMI2 and ECSEL

Read More…

Optimizing synergies between European Structural and Investment Funds and H2020

Optimizing synergies between European Structural and Investment Funds and H2020

A new Guide on Synergies between European Structural and Investment Funds (ESIF), Horizon 2020 and other innovation and competitiveness related EU programmes is now available.

Read More…

European Commission's road map to tackle Antimicrobial resistance updated

European Commission's road map to tackle Antimicrobial resistance updated

Road Map updated - Action Plan Against the rising threats from Antimicrobial Resistance

Read More…

Endomagnetics Completes Acquisition of the ACT Portfolio

Endomagnetics Completes Acquisition of the ACT Portfolio

Endomagnetics, the company developing a portfolio of products to improve the standard of cancer care, announced today the acquisition of the ACT portfolio and related assets from Actium Biosystems, LLC. This move extends Endomagnetics’ oncology platform from diagnostics into therapeutics while maintaining synergies with its magnetic nanoparticle technology.

Read More…

ETP Nanomedicine Newsletter Nr. 2/2014 published

ETP Nanomedicine Newsletter Nr. 2/2014 published

The ETPN released its Newsletter 2/2014, compiling internal news but also nanomedicine news, upcoming events, information on future calls, ...

Read More…

Registration to the ETPN Annual Event 2014 is now open!

Registration to the ETPN Annual Event 2014 is now open!

The ETPN Annual Event and General Assembly 2014 will take place on 15th and 16th October 2014 in San Sebastian (Spain). The registration facility is now open!

Read More…

Launch of the 2nd Edition of the Nanonica Prize

Launch of the 2nd Edition of the Nanonica Prize

Nanonica Prize 2014 awards scientists whose research achievements during last year represented a breakthrough in nanotechnology’s community.

Read More…

BIND Therapeutics and Roche Collaborate on Discovery of Novel Nanomedicines

BIND Therapeutics and Roche Collaborate on Discovery of Novel Nanomedicines

BIND Therapeutics Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced that it has entered into a research agreement with Roche to discover novel nanomedicines using Accurins for the treatment of diseases in therapeutic areas outside of oncology.

Read More…

Document Actions